Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Bristol-Myers Squibb Makes Significant Progress in Psoriatic Arthritis Treatment

December 29, 2024
Bristol-Myers Squibb Company, a leading pharmaceutical company, has announced promising results from two Phase 3 trials evaluating the effectiveness of its new drug, Sotyktu deucravacitinib, in treating psoriatic arthritis in adults. The trials have shown that Sotyktu hits key endpoints and provides positive outcomes for patients suffering from this debilitating condition. Institutional investors have taken notice of the positive results, with 78% of them investing in Bristol-Myers Squibb. The company's stock, traded under the symbol BMY on NYSE, has been gaining attention in the market. Although this news makes Bristol-Myers Squibb an appealing investment opportunity, it is recommended to seek guidance from professionals at Stocks Prognosis to assess the future movement of the company's stock.
If you want to leave a comment, then you need Login or Register





Other data for BMY

Related data

BMYJuly 31, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.1% Profit Achieved  ~1 min.

On April 16, 2025, QuantWave issued a short forecast signal for BRISTOL-MYERS SQUIBB COMPANY with a price of 48.72 $. Fast forward to July 31, 2025, the target price of 43....


BMYJuly 31, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Forecast Price Target with 10.86% Profit  ~1 min.

QuantWave, an automated forecasting platform, recently achieved a milestone in its prediction accuracy with the successful forecast of BRISTOL-MYERS SQUIBB COMPANY's stock movement....


BMYJune 23, 2025Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug  ~1 min.

Bristol Myers Squibb Company, a leading pharmaceutical company, is on the verge of revolutionizing cancer treatment with its groundbreaking new drug....


BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....


BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Price Target with 9.09% Profit: QuantWave Forecast Success  ~2 min.

On April 23, 2025, QuantWave's forecasting platform generated a short signal for BRISTOL-MYERS SQUIBB COMPANY stock, which was trading at $47.9 at the time....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 12.75% Profit - QuantWave Analysis  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY recently achieved the price target forecast set by QuantWave, resulting in a profitable outcome of 12.75%....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.87% Profit  ~1 min.

On May 5, 2025, QuantWave issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.41. The forecast proved accurate as the price target of $43....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.76% Profit  ~1 min.

On April 15, 2025, QuantWave, the automated forecasting platform, issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.35....


BMYDecember 29, 2024Bristol Myers Squibb: Promising Results from Phase 3 Psoriatic Arthritis Trials  ~1 min.

Bristol Myers Squibb (BMY) recently announced positive topline results from its Phase 3 trials evaluating Sotyktu deucravacitinib in adults with psoriatic arthritis....


BMYDecember 26, 2024Positive Results from Psoriatic Arthritis Trials Boost Bristol-Myers Squibb Stock  ~1 min.

Bristol-Myers Squibb Company (BMY), a leading pharmaceutical company, has recently announced positive topline results from two pivotal Phase 3 trials evaluating its drug Sotyktu deucravacitinib in adults with psoriatic arthritis. The trials have shown promising outcomes, with the drug meeting key endpoints and demonstrating effectiveness in treating the condition. Psoriatic arthritis is a chronic ...


VRTXMarch 22, 2025Vertex Pharmaceuticals VRTX: One of the Best Biotech Stocks to Buy According to Billionaires  ~2 min.

Vertex Pharmaceuticals Incorporated (VRTX) has been recognized as one of the top biotech stocks to invest in by billionaires....


REGNJanuary 3, 2025Regeneron Pharmaceuticals: A Promising Future with Strong Returns  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making waves in the pharmaceutical industry with its groundbreaking research and innovative treatments....


VRTXJanuary 12, 2025Vertex Pharmaceuticals Incorporated Faces Setbacks in Clinical Trials  ~1 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares experienced a slide recently due to setbacks in its clinical trials....